Integrated Diagnostics posts 37% revenue surge and margin gains on network expansion

Integrated Diagnostics Holdings ( (GB:IDHC) ) has provided an update.

Integrated Diagnostics Holdings reported strong financial and operational performance for 2025, with revenues climbing 37% to EGP 7.9 billion on the back of an 11% increase in test volumes and a 24% rise in average revenue per test. The group expanded its branch network from 628 to 767 locations, largely in Egypt, and continued to see growing demand despite price adjustments, while operations in conflict-hit Sudan remained largely suspended.

Profitability improved markedly as gross profit jumped 54% and EBITDA rose 61%, lifting margins through tighter cost controls, procurement efficiencies and disciplined SG&A management. Net profit rose 29% and adjusted net profit surged 79%, underpinning the board’s decision to declare a modest dividend while preserving cash for growth, including the strategic acquisition and integration of Cairo Ray for Radiotherapy to strengthen its integrated diagnostics platform.

More about Integrated Diagnostics Holdings

Integrated Diagnostics Holdings is a leading provider of medical diagnostic services operating across Egypt, Jordan, Nigeria, Saudi Arabia and Sudan. The group focuses on laboratory testing, radiology and increasingly radiotherapy, targeting both walk-in patients and corporate clients in fast-growing healthcare markets across the Middle East and Africa.

Average Trading Volume: 146,337

Technical Sentiment Signal: Buy

Current Market Cap: $372M

See more data about IDHC stock on TipRanks’ Stock Analysis page.